| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2006 | CA2584836A1 Novel azabicyclic aryl derivatives and their medical use |
| 04/20/2006 | CA2584261A1 Pharmaceutical composition |
| 04/20/2006 | CA2584185A1 Heterocyclic substituted bisarylurea derivates as kinase inhibitors |
| 04/20/2006 | CA2584179A1 N,n'-diphenylurea derivatives which are suitable as kinase inhibitors |
| 04/20/2006 | CA2584169A1 Remedies/preventives for chronic skin disease |
| 04/20/2006 | CA2584081A1 Substituted biaryl quinolin-4-ylamine analogues |
| 04/20/2006 | CA2583983A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583973A1 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583967A1 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583947A1 Compounds and methods of treating insulin resistance and cardiomyopathy |
| 04/20/2006 | CA2583920A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom |
| 04/20/2006 | CA2583918A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583846A1 Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof |
| 04/20/2006 | CA2583845A1 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt |
| 04/20/2006 | CA2583499A1 Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof |
| 04/20/2006 | CA2583457A1 Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| 04/20/2006 | CA2583353A1 Thienopyridinone compounds and methods of treatment |
| 04/20/2006 | CA2583336A1 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection |
| 04/20/2006 | CA2583333A1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 04/20/2006 | CA2583311A1 Quinazolinylmethylenethiazolinones as cdk1 inhibitors |
| 04/20/2006 | CA2583302A1 Novel oxadiazinone derivatives and use thereof as ppar-alpha modulators |
| 04/20/2006 | CA2583292A1 3-(2-hydroxyphenyl) pyrazoles and their use as hsp90 modulators |
| 04/20/2006 | CA2583253A1 Difluoro-substituted imidazopyridines |
| 04/20/2006 | CA2583243A1 Promotion of cell migration and axon regeneration in the cns |
| 04/20/2006 | CA2583192A1 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity |
| 04/20/2006 | CA2583114A1 Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them |
| 04/20/2006 | CA2583110A1 Polyamine analogs as therapeutic agents for ocular diseases |
| 04/20/2006 | CA2583101A1 Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| 04/20/2006 | CA2583096A1 Quinoxalines as b raf inhibitors |
| 04/20/2006 | CA2583092A1 Antiangiogenic calixarene-based peptide mimetics |
| 04/20/2006 | CA2583089A1 Tafi inhibitors and their use to treat pulmonary fibrosis |
| 04/20/2006 | CA2582986A1 Novel azaindole thiazolinones as anti-cancer agents |
| 04/20/2006 | CA2582985A1 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| 04/20/2006 | CA2582933A1 4-phenylsulfonamidopiperidines as calcium channel blockers |
| 04/20/2006 | CA2582674A1 Compounds for alzheimer's disease |
| 04/20/2006 | CA2582669A1 Use of aromatase inhibitors for the treatment of ectopic pregnancy |
| 04/20/2006 | CA2582639A1 Thrombin receptor antagonists |
| 04/20/2006 | CA2582593A1 Cgrp receptor antagonists |
| 04/20/2006 | CA2582588A1 Acyclic hydrazides as cannabinoid receptor modulators |
| 04/20/2006 | CA2582530A1 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| 04/20/2006 | CA2582459A1 Substituted sulfones and methods of use |
| 04/20/2006 | CA2582235A1 Lactam compounds useful as protein kinase inhibitors |
| 04/20/2006 | CA2582228A1 Method for diagnosing and treating crohn's disease |
| 04/20/2006 | CA2582202A1 Diaminoalkane aspartic protease inhibitors |
| 04/20/2006 | CA2582180A1 Indazoles, benzisoxazoles and benzisothiazoles, process for preparing them, pharmaceutical compositions and use as estrogenic agents |
| 04/20/2006 | CA2581999A1 Preparation of suspension aerosol formulations |
| 04/20/2006 | CA2581918A1 Imidazo(1,5-a)triazolo(1,5-d) benzodiazepine deratives for the treatment of cognitive disorders |
| 04/20/2006 | CA2581859A1 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel |
| 04/20/2006 | CA2581781A1 Method and intermediates for the preparation of derivatives of n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulphonamide |
| 04/20/2006 | CA2581663A1 Novel antimicrobial medicament |
| 04/20/2006 | CA2581516A1 Quinazoline derivatives |
| 04/20/2006 | CA2581493A1 Taste-masking pharmaceutical compositions |
| 04/20/2006 | CA2581188A1 Treatment of bipolar disorders and associated symptoms |
| 04/20/2006 | CA2580864A1 Method for the treatment of polycystic kidney disease |
| 04/20/2006 | CA2580862A1 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| 04/20/2006 | CA2580497A1 Substituted n-alkylpyrimidinones |
| 04/20/2006 | CA2580480A1 Pi3 kinase gamma inhibitors for the treatment of anaemia |
| 04/20/2006 | CA2580419A1 Novel insecticides |
| 04/20/2006 | CA2580268A1 Large-scale manufacturing process for the production of pharmaceutical compositions |
| 04/20/2006 | CA2580266A1 Combination of organic compounds |
| 04/20/2006 | CA2579288A1 Thiazolyldihydroindazoles |
| 04/20/2006 | CA2579279A1 Tricyclic thiazole derivatives as pi3 kinases |
| 04/20/2006 | CA2568180A1 Medical solution, method for producing and use thereof |
| 04/19/2006 | EP1647599A2 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 04/19/2006 | EP1647555A1 The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same |
| 04/19/2006 | EP1647553A1 2-acylaminothiazole derivative or salt thereof |
| 04/19/2006 | EP1647549A1 Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
| 04/19/2006 | EP1647547A1 New hydrated crystalline forms of perindopril erbumine, process for the preparation thereof and pharmaceutical formulations containing these compounds |
| 04/19/2006 | EP1647546A1 Novel heteroaryl derivative |
| 04/19/2006 | EP1647545A1 Antiviral protease inhibitors |
| 04/19/2006 | EP1647544A2 Method of obtaining inhibitors of type ii dehydroquinase enzyme and precursors thereof |
| 04/19/2006 | EP1647277A1 Glycoside-containing liposome |
| 04/19/2006 | EP1647276A1 Use of taurolidine formulations for the intramammary treatment of mastitis |
| 04/19/2006 | EP1647275A1 Solid pharmaceutical preparation |
| 04/19/2006 | EP1647274A1 Remedy for pruritus comprising piperidine derivative as the active ingredient |
| 04/19/2006 | EP1647273A1 Ophthalmic composition |
| 04/19/2006 | EP1647272A1 Curing and prophylactic agent applied during the use of alcohol and psychoactive substances |
| 04/19/2006 | EP1647271A1 4-Hydroxy tamoxifen gel formulations |
| 04/19/2006 | EP1647269A1 Matrix adjuvants and the drop pills prepared with them |
| 04/19/2006 | EP1647256A1 Dendritic cell infiltrativity activating composition and immune activator |
| 04/19/2006 | EP1647188A2 A method of controlling fungal pathogens, and agents useful for same |
| 04/19/2006 | EP1646856A2 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 04/19/2006 | EP1646659A2 Improved pharmaceutical drug candidates and methods for preparation thereof |
| 04/19/2006 | EP1646644A2 Posh interacting proteins and related methods |
| 04/19/2006 | EP1646638A2 11-12 bicyclic erythromycin derivatives |
| 04/19/2006 | EP1646635A1 Cci-779 isomer c |
| 04/19/2006 | EP1646634A1 Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
| 04/19/2006 | EP1646633A1 Beta-strand mimetics and method relating thereto |
| 04/19/2006 | EP1646629A2 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof |
| 04/19/2006 | EP1646626A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 04/19/2006 | EP1646625A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 04/19/2006 | EP1646616A2 Combretastatin derivatives with cytotoxic action |
| 04/19/2006 | EP1646614A2 Ophthalmic compositions for treating ocular hypertension |
| 04/19/2006 | EP1646612A1 Processes for preparing montelukast sodium |
| 04/19/2006 | EP1646425A1 Parasiticidal composition |
| 04/19/2006 | EP1646399A2 Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases. |
| 04/19/2006 | EP1646395A2 Methods and compositions for regulating lymphocyte activity |
| 04/19/2006 | EP1646394A2 Methods of treatment with lxr agonists |
| 04/19/2006 | EP1646393A1 A stable clozapine suspension formulation |
| 04/19/2006 | EP1646392A2 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity |